Auryxia

Akebia CEO John Butler

Pharma

FDA denies Akebia med, a 2nd blow to the oral anemia class

The FDA has issued a complete response letter to Akebia and Otsuka, denying their bid for approval of vadadustat to treat anemia associated with CKD.

Kevin Dunleavy Mar 31, 2022 8:25am

FDAApprovedStamp

Keryx looks for Auryxia boost with iron deficiency launch

Nov 8, 2017 10:45am